Last updated: 2026-09-29 07:09:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Tvardi Therapeutics, Inc. (TVRD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.33, with a market capitalization of $16.94M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.93 to $43.65. This page covers its latest market performance, valuation, price trends and company information.
$16.94M | |
$1.27 | |
$43.65 | |
$0.93 | |
$1.27 | |
339.80K | |
2.28M | |
-- | |
$43.65 | |
$0.93 | |
-- | |
-- |
Tvardi Therapeutics, Inc. (TVRD) last closed at $1.27 as of 2026-09-28 23:45:00, unchanged from the previous close of $1.27.
During the latest regular trading session, TVRD traded between $0.93 and $43.65, with a volume of 339.80K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Tvardi Therapeutics, Inc. (TVRD) moved from $1.63 to $1.33, representing a decline of 18.65% ($0.30).
The stock traded between $0.93 and $1.73 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 352.65 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.9%
TVRD is currently trading at $1.33, placing it 0.9% of the way from its 52-week low of $0.93 to its 52-week high of $43.65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 12 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tvardi Therapeutics, Inc. (TVRD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.